TEVA-GLYBURIDE 2.5 MG — DIN 01913670
GLYBURIDE : 2.5 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-GLYBURIDE?
TEVA-GLYBURIDE 2.5 MG contains GLYBURIDE : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 01913670, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Oct-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-GLYBURIDE used for?
TEVA-GLYBURIDE (glyburide) is indicated as an adjunct to proper dietary management, exercise and weight reduction to lower blood glucose in adult patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone or when insulin therapy is not required.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Glibenclamide cost around the world?
Glibenclamide is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 17 | 21 | SAR███.██ |
| South Africa | single exit price | 10 | 19 | ZAR███.██ |
| Morocco | PPV (public price) | 6 | 14 | MAD███.██ |
| United Arab Emirates | public | 5 | 7 | AED███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
69 pack listings across 44 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Glibenclamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Glibenclamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
19 holders have a Canadian DIN containing Glibenclamide, across 44 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 4 | 2 | NTP-GLYBURIDE, TEVA-GLYBURIDE | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO GLYBURIDE TAB 2.5MG, APO GLYBURIDE TAB 5MG | Sourceable in Canada |
| PHARMASCIENCE INC | 4 | 0 | EUGLUCON, PMS-GLYBURIDE | No marketed DIN |
| PRO DOC LIMITEE | 4 | 0 | GLYBURIDE, GLYBURIDE-5 TAB 5MG, PRO-GLYBURIDE | No marketed DIN |
| HOECHST ROUSSEL CANADA INC. | 2 | 0 | DIABETA TAB 5MG, DIABETA TABLETS 2.5MG | No marketed DIN |
| LABORATOIRE RIVA INC. | 2 | 0 | RIVA-GLYBURIDE | No marketed DIN |
| MEDICAN PHARMA INCORPORATED | 2 | 0 | MED GLYBE TAB 2.5MG, MED GLYBE TAB 5MG | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-GLYBE | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-GLYBURIDE TAB 2.5MG, NU-GLYBURIDE TAB 5MG | No marketed DIN |
| PENTAPHARM LTD. | 2 | 0 | PENTA-GLYBURIDE - 2.5MG, PENTA-GLYBURIDE - 5MG | No marketed DIN |
| PHARMEL INC | 2 | 0 | RIVA-GLYBURIDE | No marketed DIN |
| PREMPHARM INC | 2 | 0 | GLYBURIDE TABLETS 2.5MG, GLYBURIDE TABLETS 5MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Glibenclamide |
|---|---|
| ATC code | A10BB01 |
| AHFS class | 68:20.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01913670 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1913670 |
| Brand name | TEVA-GLYBURIDE |
| Generic / active ingredient | GLYBURIDE : 2.5 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | A10BB01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BB |
| Current status | MARKETED |
| Status date | 09-Oct-2010 |
| Original market date | 1991-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 44 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO GLYBURIDE TAB 2.5MG | 2.5 MG | TABLET | APOTEX INC | MARKETED | 01913654 |
| APO GLYBURIDE TAB 5MG | 5 MG | TABLET | APOTEX INC | MARKETED | 01913662 |
| TEVA-GLYBURIDE | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 01913689 |
| AVA-GLYBURIDE | 5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | 02363712 |
| AVA-GLYBURIDE | 2.5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | 02363704 |
| DIABETA | 2.5 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02224550 |
| DIABETA | 5 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02224569 |
| DIABETA 5MG | 5 MG | TABLET | HOECHST CANADA INC. | CANCELLED POST MARKET | 00012599 |
| DIABETA TAB 2.5MG | 2.5 MG | TABLET | HOECHST CANADA INC. | CANCELLED POST MARKET | 00454753 |
| DIABETA TAB 5MG | 5 MG | TABLET | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | 01987836 |
2 · Same class — other molecules in ATC A10BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Gliclazide | AG-GLICLAZIDE MR · APO-GLICLAZIDE · APO-GLICLAZIDE MR · AVA-GLICLAZIDE · +17 more | 30 | 16 | Yes |
| Glibenclamide | APO GLYBURIDE TAB 2.5MG · APO GLYBURIDE TAB 5MG · AVA-GLYBURIDE · DIABETA · +24 more | 44 | 4 | Yes |
| Glimepiride | AMARYL · APO-GLIMEPIRIDE · CO GLIMEPIRIDE · NOVO-GLIMEPIRIDE · +3 more | 22 | 3 | Yes |
| Chlorpropamide | APO CHLORPROPAMIDE TAB 100MG · APO CHLORPROPAMIDE TAB 250MG · CHLORPROPAMIDE 100 TAB USP · CHLORPROPAMIDE TAB 250MG · +3 more | 8 | 0 | Not in Canada |
| Tolbutamide | MOBENOL TABLETS 500MG · NOVO-BUTAMIDE 500MG · ORINASE 0.5GM · ORINASE 1GM · +2 more | 7 | 0 | Not in Canada |
| Acetohexamide | DIMELOR TABLET 1843 500MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-GLYBURIDE called?
The same molecule, Glibenclamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| GLIPHARM | Latin | Morocco |
| Daonil | Latin | Australia, Morocco |
| Glucovance | Latin | Saudi Arabia |
| Glycomin | Latin | South Africa |
| BENCLAMID | Latin | Morocco |
| GLIBENCLAMIDE | Latin | Lebanon |
| GLIDIABET | Latin | Morocco |
| MELIX | Latin | Morocco |
| BI-ACT | Latin | Bahrain |
| Diacare | Latin | South Africa |
| Euglucon | Latin | South Africa |
| Glibil | Latin | Saudi Arabia |
| HEMIDAONIL | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.